U.S. markets open in 4 hours 37 minutes

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
109.75+1.14 (+1.05%)
At close: 4:03PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close108.61
Open109.11
Bid0.00 x 1000
Ask0.00 x 800
Day's Range107.78 - 109.86
52 Week Range69.52 - 127.68
Volume904,024
Avg. Volume1,002,420
Market Cap18.695B
Beta (5Y Monthly)1.45
PE Ratio (TTM)37.17
EPS (TTM)2.95
Earnings DateAug 30, 2021 - Sep 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est134.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-17% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
    Zacks

    Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate

    Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.

  • Business Wire

    Catalent, Inc. to Present at the Biopharma CEO Investor Forum

    Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that John Chiminski, Chair and Chief Executive Officer, will virtually present at the Biopharma CEO Investor Forum at 9:45 a.m. ET on June 8, 2021.

  • AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
    Benzinga

    AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT

    AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (NYSE: EBS) Baltimore plant to a factory owned by Catalent Inc (NYSE: CTLT), the New York Times reported. The company has been on the lookout for an alternative production site since the U.S. government stopped it from using Emergent’s Baltimore plant after workers accidentally contaminated a batch of Johnson & Johnson’s (NYSE: JNJ) vaccine wi